Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
- First-in-human intradermal administration of CoronaTcP™ was generally well-tolerated - [...]
Emergex Appoints Sir Michael Rake as Board Chairman
Highly experienced international Board Leader joins Emergex as the company [...]
Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates
Emergex and Brazil’s IBMP to co-fund Phase II and Phase [...]
Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no [...]
Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of [...]
Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox
- Vaccine construct comprised predominantly of peptides from early “eclipse [...]
Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma
Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding Limited [...]
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex will manufacture the candidate universal influenza vaccine to cGMP [...]
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding [...]
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
- Emergex’s COVID-19 and Dengue CD8+ T cell Adaptive vaccines [...]